Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Donepezil containing medicinal products - Direct communication with healthcare professionals on Donepezil containing medicinal products
Direct communication with healthcare professionals on Donepezil containing medicinal products

Donepezil containing medicinal products: Addition to the product safety information regarding cardiac conductions disorders including QT prolongation and Torsade de Pointes.
Summary
- There have been post-marketing reports of QTc interval prolongation and Torsade de Pointes in association with donepezil therapy
- Caution is advised in patients with pre-existing or family history of QTc prolongation
- Caution is advised in patients with concomitant treatment with medicinal products that affect the QTc interval or induce bradycardia
- Caution is advised in patients with relevant heart disease or electrolyte disturbances. At risk patients should be considered for monitoring with electrocardiograms (ECG).
- Addition of undesirable effects: Polymorphic ventricular tachycardia including Torsade de Pointes, Electrocardiogram QT interval prolonged
- Update of Drug interactions
Published on: 07 February 2022
📅 Giornata Mondiale della Salute Mentale | 10 ottobre 2026
AIFA celebra la Giornata mondiale dell...
Vai al post →
🌍 Oggi si celebra la Giornata Mondiale della Consapevolezza PANS/PANDAS e #AIFA si unisce alla camp...
Vai al post →
🤝 Nell’ambito di “AIFA Ascolta”, spazio di confronto e dialogo tra l’Agenzia e le associazioni che ...
Vai al post →
Appropriatezza prescrittiva, revisione delle Note AIFA e dei Piani Terapeutici: questi i principali ...
Vai al post →
È online il nuovo corso FAD del progetto COSIsiFA “Antimicrobico resistenza: l’approccio One Health”...
Vai al post →
🔎 Quanto vale davvero un’innovazione terapeutica?
Non solo efficacia, sicurezza e costi: valutare ...
Vai al post →
